GlassScriptPhysician profile
Raymond Ruberg
NPI 1508806175
$5,579.19
in general payments reported to CMS, 2019-2025
20 companies · $435 in 2025
The $435 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,452 · 2020: $211 · 2021: $569 · 2022: $1,289 · 2023: $1,190 · 2024: $433 · 2025: $435.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,058.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,058.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,263.53 | 2019-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $910.40 | 2019-2025 | Airsupra, Farxiga |
| Lilly USA, LLC | $296.28 | 2022-2025 | Mounjaro |
| Abbvie INC. | $267.36 | 2023 | Qulipta, Vraylar, Ubrelvy |
| Glaxosmithkline, LLC. | $266.85 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amarin Pharma, INC. | $229.82 | 2019 | |
| Phathom Pharmaceuticals, INC. | $180.60 | 2024 | Voquezna |
| Medtronic Vascular, INC. | $131.00 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $122.60 | 2021 | |
| Abbott Laboratories | $116.85 | 2023 | Freestyle Libre 3, Freestyle Libre |
| Janssen Pharmaceuticals, INC | $111.68 | 2019 | |
| Exact Sciences Corporation | $109.65 | 2023 | Cologuard Collection Kit |
| Mylan Specialty L.P. | $108.44 | 2023 | Yupelri |
| Bayer Healthcare Pharmaceuticals INC. | $103.75 | 2022 | |
| Merck Sharp & Dohme LLC | $102.40 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $79.78 | 2019-2023 | Stiolto Respimat |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $63.93 | 2023 | |
| Genzyme Corporation | $57.86 | 2023 | |
| Amgen INC. | $41.06 | 2019 | |
| Dexcom, INC. | $15.35 | 2023 | Dexcom G6 Transmitter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raymond Ruberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.